Biology:Razi Cov Pars
From HandWiki
Revision as of 08:26, 22 October 2021 by imported>SpringEdit (fix)
Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
Razi Cov Pars is a COVID-19 vaccine candidate developed by Razi Vaccine and Serum Research Institute.[1][2][3]
References
- ↑ Mehdi, Syed Zafar (7 February 2021). "Iran unveils second homegrown COVID-19 vaccine". Anadolu Agency. https://www.aa.com.tr/en/latest-on-coronavirus-outbreak/iran-unveils-second-homegrown-covid-19-vaccine/2136654.
- ↑ "Phase I, Safety and Immunogenicity of Razi SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars), in healthy adults aged 18-55 years; parallel 4 arms design (adjuvant only and three vaccine doses of 5, 10, and 20 µg/200µl); a Randomised, double blind, clinical trial". Iranian Registry of Clinical Trials. https://www.irct.ir/trial/52975.
- ↑ "Phase II, Safety and Immunogenicity of RAZI SARS-CoV-2 recombinant Spike protein vaccine (RAZI Cov Pars) in adults aged 18-70 years; a Randomised, double blind, parallel 2 arms clinical trial". Iranian Registry of Clinical Trials. https://en.irct.ir/trial/55238.
 |
